Japan CAR-T Therapy Landscape
Japan CAR-T therapy - Competitive landscapeJapan pharma catching-up with global players… but a large gap remains Novartis AG (NOVN SE)’ Kymriah...
1.3k Views
Takeda Pharmaceutical: Looking Forward To Pending Approvals and Late Stage Pipeline in FY27
Takeda Pharmaceutical reported lower FY26 revenue due to generic erosion, but expects growth in FY27 driven by new launches and core brands, with...
146 Views
Shionogi & Co (4507 JP): FY26 Result Falls Short of Expectation; Mixed Guidance for FY27
Shionogi announces FY26 results, with revenue meeting but operating profit missing guidance due to higher expenses. The company expects 32%...
96 Views
Daiichi Sankyo (4568 JP): Ends FY26 on Mixed Note; It’s Time to Focus on Innovation Prowess
Daiichi Sankyo aims to become a global top five oncology company with ¥2.3T+ oncology revenue by 2030, by maximize the value of its DXd ADC...
98 Views
Sector Capsule: Sports Drinks in Japan
Sports drinks declined by 5% in off-trade volume terms to 1,344 million litres and declined by 6% in off-trade current value terms to JPY301.0...
336 Views